Nexalin Technology Breakthrough Study on Alzheimer's Disease
HOUSTON, TX — Nexalin Technology, Inc. (NASDAQ: NXL; NXLIW) has recently published a significant study in the Journal of Alzheimer's Disease about the impact of its innovative deep intracranial frequency stimulation (DIFS) technology on Alzheimer's disease (AD). This study marks a pivotal advancement in exploring non-invasive approaches to enhance neurocognitive functions in patients experiencing mild stages of AD.
Study Overview and Methodology
In this landmark investigation, 46 patients were randomly chosen to undergo either real DIFS or a sham treatment over 30 sessions in just three weeks. Researchers utilized resting-state functional magnetic resonance imaging (rs-fMRI) to monitor and analyze alterations in brain activity. The results indicated that Nexalin’s proprietary DIFS technology significantly modifies neuronal activity in critical brain areas, marking a breakthrough in non-pharmacological options for Alzheimer’s treatment.
Key Insights from the Research
Boost in Neuronal Activity and Metabolic Function
The study's findings revealed substantial elevations in the fractional amplitude of low-frequency fluctuation (fALFF) in the prefrontal cortex among participants who received actual DIFS treatment. This increase indicates heightened spontaneous neuronal activity—an essential factor in relation to cognitive functions, which often decline in Alzheimer’s patients due to impaired glucose metabolism.
Sustained Cognitive Benefits Observed
Remarkably, improvements in cognitive functions were evident after the three-week treatment period, and these enhancements persisted for three months after. Enhanced neuronal activity was measured in the superior parietal lobule and inferior temporal gyrus—regions vital for cognitive and memory processes. This suggests that DIFS may provide long-lasting cognitive support for Alzheimer’s patients.
Increased Brain Connectivity
The study also demonstrated improved regional homogeneity (ReHo) across several brain areas, indicating enhanced synchronization between neural activities. The ability of DIFS to improve communication among different brain networks highlights its promise in enhancing cognitive processes through better brain connectivity.
Positive Correlation with Blood Flow and Brain Function
Enhanced blood flow in several key regions corresponded with increased neuronal activity and improved metabolic functions. The study noted that enhancements in both glucose metabolism and cerebral blood flow were particularly marked in areas associated with memory. These results align closely with prior findings regarding DIFS and set a strong precedent for its role as a non-invasive treatment for Alzheimer’s.
Safety Profile of DIFS Treatment
Crucially, the study reported no severe side effects among participants. Elderly patients tolerated DIFS exceptionally well, experiencing only minor sensations such as temporary tingling. This safety profile is essential when considering treatment for sensitive populations such as those living with Alzheimer’s.
The Global Context of Alzheimer's Disease
With over 50 million individuals afflicted by Alzheimer's disease globally—a number projected to exceed 113 million by 2050—the need for innovative therapies is urgent. While current treatments focus mainly on mitigating symptoms, the DIFS technology by Nexalin opens doors to targeting the fundamental reasons behind cognitive deterioration.
Nexalin's Ongoing Commitment to Research
This recent research report forms part of Nexalin's ongoing efforts to push boundaries in neurological treatments. Previous studies have shown significant improvements in memory and cognitive functions among Alzheimer’s patients utilizing DIFS technology, with enhancements in Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores and notable results in neural activity in the hippocampus, a brain region critical to memory.
Dr. David Owens, Nexalin’s Chief Medical Officer, expressed optimism about the findings: “The results of this study support our belief that DIFS effectively enhances cognitive function. Its safety in elderly populations adds credibility to our approach.”
Mark White, CEO of Nexalin Technology, emphasized the importance of this milestone: “The outcomes of this study are promising. They reinforce our commitment to develop non-invasive methods to improve cognitive health and alleviate the burden of Alzheimer's disease.”
About Nexalin Technology, Inc.
Nexalin Technology designs and develops diverse neurostimulation products to confront the growing mental health crisis globally. Their emphasis on non-invasive solutions aims to assist individuals encountering significant mental health challenges. The company leverages bioelectronic medical technology to achieve therapeutic effects while ensuring patient safety.
Frequently Asked Questions
What is the DIFS technology developed by Nexalin?
DIFS, or deep intracranial frequency stimulation, is a non-invasive neurostimulation approach designed to enhance brain function and cognitive performance.
How many patients participated in the study?
The study included 46 patients, who were either given real DIFS treatment or a sham procedure over a period of three weeks.
What were the main findings of the research?
The study found increased neuronal activity, improved cognitive function, enhanced brain connectivity, higher blood flow, and a favorable safety profile for DIFS treatment.
How safe is the DIFS treatment according to the study?
A notable aspect of the study was its report of no serious side effects, with participants tolerating the treatment well.
What future steps is Nexalin planning related to DIFS?
Nexalin is dedicated to continuing its research on DIFS and pursuing larger clinical trials to further validate the effectiveness and safety of the treatment for Alzheimer's patients.
